Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine-Reference-Cited by-同舟云学术

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Published:2018-11-14 Issue:3 Volume:15 Page:540-548
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Peterson James T.¹,Stacey Helen L.²^ORCID,MacNair John E.³,Li Jianing³,Hartzel Jonathan S.³,Sterling Tina M.³,Benner Patrice³,Tamms Gretchen M.³,Musey Luwy K.³

Affiliation:

1. Foothill Family Clinic, Salt Lake City, USA

2. Diablo Clinical Research, Walnut Creek, USA

3. Merck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, USA

Funder

Merck

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2018.1532250

Reference35 articles.

1. Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

2. Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report: emerging infections program network streptococcus pneumoniate, provisional-2009 [web-based report]. [accessed 2018 Mar 29] http://www.cdc.gov/abc.

3. Epidemiology of Invasive Streptococcus pneumoniae Infections in the United States, 1995-1998Opportunities for Prevention in the Conjugate Vaccine Era

4. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report emerging infections program network streptococcus pneumoniae, 1997 [web-based report]. [accessed 2018 Mar 29]. http://www.cdc.gov/ncidod/dbmd/abcs.

5. Healthcare utilization and cost of pneumococcal disease in the United States

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pneumococcal serotypes and risk factors in adult community acquired pneumonia 2018–20: a multicentre UK cohort study;The Lancet Regional Health - Europe;2024-02

2. An insights into emerging trends to control the threats of antimicrobial resistance (AMR): an address to public health risks;Archives of Microbiology;2024-01-22

3. Recommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition;Infection & Chemotherapy;2024

4. Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children;Frontiers in Public Health;2023-12-20

5. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age;Vaccine;2023-10